1. Home
  2. AOMR vs TVRD Comparison

AOMR vs TVRD Comparison

Compare AOMR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AOMR
  • TVRD
  • Stock Information
  • Founded
  • AOMR 2018
  • TVRD 2017
  • Country
  • AOMR United States
  • TVRD United States
  • Employees
  • AOMR N/A
  • TVRD N/A
  • Industry
  • AOMR Real Estate Investment Trusts
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • AOMR Real Estate
  • TVRD Health Care
  • Exchange
  • AOMR Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • AOMR 211.5M
  • TVRD 246.5M
  • IPO Year
  • AOMR 2021
  • TVRD N/A
  • Fundamental
  • Price
  • AOMR $9.84
  • TVRD $29.92
  • Analyst Decision
  • AOMR Strong Buy
  • TVRD Strong Buy
  • Analyst Count
  • AOMR 6
  • TVRD 5
  • Target Price
  • AOMR $11.25
  • TVRD $59.20
  • AVG Volume (30 Days)
  • AOMR 225.2K
  • TVRD 23.2K
  • Earning Date
  • AOMR 08-05-2025
  • TVRD 08-14-2025
  • Dividend Yield
  • AOMR 12.98%
  • TVRD N/A
  • EPS Growth
  • AOMR N/A
  • TVRD N/A
  • EPS
  • AOMR 1.56
  • TVRD N/A
  • Revenue
  • AOMR $57,661,000.00
  • TVRD N/A
  • Revenue This Year
  • AOMR N/A
  • TVRD N/A
  • Revenue Next Year
  • AOMR $13.75
  • TVRD N/A
  • P/E Ratio
  • AOMR $6.31
  • TVRD N/A
  • Revenue Growth
  • AOMR N/A
  • TVRD N/A
  • 52 Week Low
  • AOMR $7.36
  • TVRD $8.13
  • 52 Week High
  • AOMR $11.51
  • TVRD $34.31
  • Technical
  • Relative Strength Index (RSI)
  • AOMR 57.41
  • TVRD 65.43
  • Support Level
  • AOMR $9.61
  • TVRD $22.91
  • Resistance Level
  • AOMR $9.81
  • TVRD $31.54
  • Average True Range (ATR)
  • AOMR 0.20
  • TVRD 1.65
  • MACD
  • AOMR 0.02
  • TVRD 0.61
  • Stochastic Oscillator
  • AOMR 78.31
  • TVRD 81.28

About AOMR Angel Oak Mortgage REIT Inc.

Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: